

JCEM PROOFS: PLEASE REVIEW YOUR ARTICLE (# 8988) from The Journal of Clinical Endocrinology and Metabolism is available for download

=====

The Journal of Clinical Endocrinology and Metabolism Published by The Endocrine Society

Dear Author:

Please refer to this URL address

<http://cpcb-ftp.cadmus.com/cgi-bin/s-proof/login?841201>

Login: your e-mail address

Password: ----

The site contains 1 file. You will need to have Adobe Acrobat® Reader software to read these files. This is free software and is available for user downloading at <http://www.adobe.com/products/acrobat/readstep.html>.

This file contains:

- 1) Page proofs for your article in The Journal of Clinical Endocrinology and Metabolism, including author queries that require a response
- 2) Reprint Order Form

Page Proofs.

After printing the PDF file, please read the page proofs carefully and:

- 1) indicate changes or corrections in the margin of the page proofs (please write neatly in dark ink);
- 2) answer all queries (footnotes A,B,C, etc.) on the last page of the PDF proof (insert changes where needed on the page proofs);
- 3) proofread any tables and equations carefully;
- 4) check that any Greek, especially  $\mu$  (mu), has translated correctly;
- 5) if you have any concerns about the quality of your figures, please note your concerns on the page proofs; if you need to submit corrected figures, see the note below.
- 6) consult the most recent Instructions to Authors for the list of standard abbreviations for this journal if you have any questions. Please note that these instructions were updated in 2001.

Within 48 hours, please make yourself a copy of your corrected page proofs and return the following (by special courier) to the address given below:

- 1) original PDF set of page proofs
- 2) corrected figures (if necessary) if submitted on disk must meet the requirements shown on the digital art Web site ([www.cjs.cadmus.com/da](http://www.cjs.cadmus.com/da)); a good quality original hard copy of the figure must also be provided with or without a disk

Reprint Order Forms and Publication Charges. All regular articles are subject to publication charges, with the exception of invited articles. The Reprint Order Form should be signed and completed, even if you are not ordering reprints. Send the form to: The Endocrine Society, c/o Bank of America, P.O. Box 631048,

# **The Journal of Clinical Endocrinology and Metabolism**

**Article No. eg8988**

Copy of e-mail Notification

Baltimore, Maryland 21263-1048. Reference the month of publication and the 6-digit reprint order number on your correspondence.

If you have any questions regarding the text or figures in your article, please contact me. If you have any questions about access to your PDF file or wish to see Iris proofs of your color figures, please contact the account manager, Joy Williams, at 410-691-6439 or [williamsj@cadmus.com](mailto:williamsj@cadmus.com).

Sincerely,

Sheri Harris  
Journal Production Editor  
The Journal of Clinical Endocrinology and Metabolism  
Cadmus Professional Communications  
940 Elkridge Landing Road  
Linthicum, Maryland 21090-2908  
Phone: 410-691-6991; Fax: 410-684-2792  
E-mail: [harriss@cadmus.com](mailto:harriss@cadmus.com)

# The Journal of Clinical Endocrinology & Metabolism 2002

## Author order form or proforma invoice

(Please keep a copy of this document for your records.)

Author reprint orders and/or prepayments must be received 2 weeks before publication. Please fax the Cadmus Reprint Department at 410-820-9765 by this date if your article contains color and you wish to order reprints.

Author Name: \_\_\_\_\_  
Title of Article: \_\_\_\_\_  
Issue of Journal: \_\_\_\_\_ Reprint # 1022756 Publication Date: \_\_\_\_\_  
No. of Pages: 6 Manuscript # 020878  
Color in Article: Yes / No (Please Circle)

*Please include the journal name and reprint number or manuscript number on your purchase order or other correspondence.*

### Reprint Costs (Please see reverse side for reprint costs.)

\_\_\_\_\_ number of reprints ordered \$ \_\_\_\_\_  
Add color in reprints, \$75 per  
100 copies and up to 500 copies. \$ \_\_\_\_\_  
Add reprint covers, \$130 per first 100 copies,  
plus \$30 for each additional 100 copies \$ \_\_\_\_\_  
Taxes \$ \_\_\_\_\_  
*(Add appropriate sales tax for Virginia, Maryland, Pennsylvania, and the  
District of Columbia or Canadian GST to the reprints if your order is to be  
shipped to these locations.)*  
Add \$30.00 for each additional ship location \$ \_\_\_\_\_

### Publication Fees

Page Charges, \$90.00 per page \$ \_\_\_\_\_  
Color Figures, \$525 for each color figure \$ \_\_\_\_\_  
**Total Amount Due** \$ \_\_\_\_\_  
(Reprint Cost & Publication Fees)

### Ordering Details

#### Invoice Address

Name \_\_\_\_\_  
Institution \_\_\_\_\_  
Street \_\_\_\_\_  
Department \_\_\_\_\_  
City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
Country \_\_\_\_\_  
Phone \_\_\_\_\_ Fax \_\_\_\_\_  
E-mail \_\_\_\_\_  
Purchase Order No. \_\_\_\_\_

### Shipping Address

Name \_\_\_\_\_  
Street \_\_\_\_\_  
City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
Country \_\_\_\_\_  
Quantity \_\_\_\_\_ Fax \_\_\_\_\_  
Phone \_\_\_\_\_ E-mail \_\_\_\_\_

### Additional Shipping Address\*

Name \_\_\_\_\_  
Street \_\_\_\_\_  
City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
Country \_\_\_\_\_  
Quantity \_\_\_\_\_ Fax \_\_\_\_\_  
Phone \_\_\_\_\_ E-mail \_\_\_\_\_

\*Add \$30.00 for each additional shipping address

### Credit Card Payment Details

Credit Card: \_\_\_ VISA \_\_\_ Am. Exp. \_\_\_ MasterCard  
Card Number: \_\_\_\_\_  
Expiration Date: \_\_\_\_\_  
Signature: \_\_\_\_\_

Send your order form and payment made payable to:

The Endocrine Society  
c/o Bank of America  
P.O. Box 631048  
Baltimore, MD 21263-1048

**Note: Do not send express packages to this location.**

IT IS THE POLICY OF CADMUS REPRINTS TO ISSUE ONE INVOICE PER ORDER.

**Enclosed: Personal Check \_\_\_\_\_ Institutional Purchase Order \_\_\_\_\_ Credit Card Payment Details \_\_\_\_\_**  
Checks must be paid in U.S. dollars and drawn on a U.S. Bank. Credit cards are processed by Cadmus.

Signature: \_\_\_\_\_ Date: \_\_\_\_\_  
Signature is required. By signing this form, the author agrees to accept the responsibility for the payment of reprints and/or all charges described in this document.

# The Journal of Clinical Endocrinology & Metabolism

2002 AUTHOR REPRINT AND PUBLICATION CHARGES

## Black-and-White Reprint Prices

Domestic Copies (USA Only)					
# of Pages	100	200	300	400	500
1-4	\$247	\$280	\$322	\$352	\$385
5-8	\$405	\$461	\$534	\$599	\$656
9-12	\$548	\$635	\$743	\$836	\$927
13-16	\$692	\$810	\$957	\$1,074	\$1,195
17-20	\$840	\$983	\$1,170	\$1,315	\$1,458

International Copies (includes Canada and Mexico)					
# of Pages	100	200	300	400	500
1-4	\$277	\$316	\$359	\$397	\$442
5-8	\$436	\$505	\$595	\$675	\$753
9-12	\$584	\$698	\$830	\$946	\$1,063
13-16	\$737	\$885	\$1,067	\$1,215	\$1,370
17-20	\$893	\$1,074	\$1,305	\$1,488	\$1,675

Minimum order is 100 copies. Maximum order using this form is 500 copies. For articles longer than 20 pages, please consult Cadmus Reprints at 800-407-9190. For orders larger than 500 copies, contact Debbie Heise (tel) 410-691-6274, (fax) 410-684-2789, endoreprints@cadmus.com.

## Color in Reprints

Add \$75.00 per 100 copies (upto 500 copies) to the cost of reprints if the article contains any color in addition to black. For pricing of color articles with a quantity greater than 500 copies, please contact Cadmus Reprints at 410-691-6274, endoreprints@cadmus.com.

**Reprint Covers** Add \$130.00 per first 100 copies, plus \$30.00 for additional 100 copies.

## Publication Fees

### Page Charges

Add \$90.00 per journal page for all pages in the article. Page charges are not levied for papers specifically invited by the Editor-in-Chief.

## Articles Published with Color Figures

If your article contains color, add \$525 for each color figure. Please state the exact color figure charge on the reverse side and add to your payment or purchase order accordingly. (Author color charges do not apply to author of invited papers, provided the photographs have been approved by the Editor-in-Chief.)

**AUTHOR REPRINT ORDER FORMS  
AND/OR PREPAYMENTS MUST BE  
RECEIVED 2 WEEKS BEFORE  
PUBLICATION**

## Shipping

UPS ground within the United States (1-5 days delivery) is included in the reprints prices. Orders shipped to author outside the United States are mailed via an expedited air service.

## Multiple Shipments

You may request that your order be shipped to more than one location. Please be aware that it will cost \$30.00 for each additional location.

## Delivery

Your order will be shipped within 2 weeks of the journal print date. Allow extra time for delivery.

## Tax Due

Residents of Virginia, Maryland, Pennsylvania, and the District of Columbia are required to add the appropriate sales tax to each reprint order. For orders shipped to Canada, please add 7% Canadian GST unless exemption is claimed.

## Publishing Requirements

The Endocrine Society requires prepayment or a signed institutional purchase order covering the full amount of your page charges, color charges, and reprint charges before your article will be published. You must return this form with payment of page and color charges even if you are not ordering reprints. Return this order form with check, credit card information, or signed purchase order to:

The Endocrine Society  
c/o Bank of America  
P.O. Box 631048  
Baltimore, MD 21263-1048

Please direct all inquiries to Menna Burgess:

800-407-9190 (toll-free number)  
410-819-3960 (direct number)  
410-820-9765 (FAX number)  
BurgessM@cadmus.com (E-mail address)

# Neurosteroid Quantification in Human Brain Regions: Comparison between Alzheimer's and Nondemented Patients

SÉBASTIEN WEILL-ENGERER, JEAN-PHILIPPE DAVID, VÉRONIQUE SAZDOVITCH, PHILIPPE LIERE, BERNARD EYCHENNE, ANTOINE PIANOS, MICHAEL SCHUMACHER, ANDRÉ DELACOURTE, ETIENNE-EMILE BAULIEU, AND YVETTE AKWA

INSERM, U-488 (S.W.E., P.L., B.E., A.P., M.S., E.E.B., Y.A.), Le Kremlin-Bicêtre, France; Assistance Publique-Hôpitaux de Paris, Hôpital Rothschild, Service de Gériatrie (S.W.E.), Paris, France; INSERM, U-422 (J.P.D., A.D.), Lille, France; Assistance Publique-Hôpitaux de Paris, Hôpital Emile Roux, Service de Gériatrie 3 (J.P.D.), Limeil Breuvannes, France; and Assistance Publique-Hôpitaux de Paris, Service d'Anatomie Pathologique Neurologique, Hôpital Pitié-Salpêtrière (V.S.), Paris, France

Some neurosteroids have been shown to display beneficial effects on neuroprotection in rodents. To investigate the physiological significance of neurosteroids in Alzheimer's disease (AD), we compared the concentrations of pregnenolone, pregnenolone sulfate (PREGS), dehydroepiandrosterone, dehydroepiandrosterone sulfate (DHEAS), progesterone, and allopregnanolone, measured by gas chromatography-mass spectrometry, in individual brain regions of AD patients and aged nondemented controls, including hippocampus, amygdala, frontal cortex, striatum, hypothalamus, and cerebellum. A general trend toward decreased levels of all steroids was observed in all AD patients' brain regions compared with controls: PREGS and DHEAS were significantly lower in the striatum and cerebellum,

and DHEAS was also significantly reduced in the hypothalamus. A significant negative correlation was found between the levels of cortical  $\beta$ -amyloid peptides and those of PREGS in the striatum and cerebellum and between the levels of phosphorylated  $\tau$  proteins and DHEAS in the hypothalamus. This study provides reference values for steroid concentrations determined by gas chromatography-mass spectrometry in various regions of the aged human brain. High levels of key proteins implicated in the formation of plaques and neurofibrillary tangles were correlated with decreased brain levels of PREGS and DHEAS, suggesting a possible neuroprotective role of these neurosteroids in AD. (*J Clin Endocrinol Metab* 87: 0000–0000, 2002)

A VARIETY of steroids can be synthesized in the rodent brain independently of peripheral glandular sources. Such steroids formed within the brain from cholesterol are defined as neurosteroids (1). Among them, neuroactive neurosteroids are allosteric modulators of the neurotransmitter receptor activities (2), hence regulating different aspects of animal behavior (3, 4). Particularly relevant to the aging process and Alzheimer disease (AD) are the beneficial effects of neurosteroids on memory (5) and neuroprotection against the  $\beta$ -amyloid peptide-induced neurotoxicity *in vitro* (6–8). In the human brain some studies have reported quantification of several neurosteroids, such as pregnenolone (PREG; 3 $\beta$ -hydroxy-pregn-5-ene-20-one), pregnenolone sulfate (PREGS), dehydroepiandrosterone (DHEA; 3 $\beta$ -hydroxy-androst-5-ene-17-one), DHEA sulfate (DHEAS), and allopregnanolone (3 $\alpha$ ,5 $\alpha$ -THP; 3 $\alpha$ -hydroxy-5 $\alpha$ -pregnan-20-one). However, most of them have used subjects with a wide range of ages, between 2–85 yr (9–11), except for the one by Lacroix *et al.* (12) that used 76- to 93-yr-old subjects whose neurological status was not mentioned.

Abbreviations: A $\beta$ ,  $\beta$ -Amyloid peptides; AD, Alzheimer's disease; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; GC-MS, gas chromatography-mass spectrometry; NFT, neurofibrillary tangles; PHF, paired helical filaments; PHF- $\tau$ , paired helical filaments that result from the aggregation of pathologic  $\tau$  proteins; PREG, pregnenolone; PREGS, pregnenolone sulfate; PROG, progesterone; 3 $\alpha$ ,5 $\alpha$ -THP, allopregnanolone.

Normal aging is accompanied by numerous physiological, behavioral, and hormonal changes. One of the most prominent endocrine changes is the continuous decrease with age in the blood levels of steroids. Besides the age-related decrease in circulating concentrations of estradiol (in menopause) and testosterone (in andropause), a significant fall also occurs in plasma in both women and men, for PREG, PREGS, DHEA, DHEAS, and 3 $\alpha$ ,5 $\alpha$ -THP (13). Whether the profound age-related reduction in the blood concentrations of these steroids is associated with AD is still unclear. Only DHEAS and DHEA have been measured in the blood of AD patients in comparison with nondemented controls, but results were rather contradictory (14–17). To the best of our knowledge, there is no study examining the brain levels of neurosteroids in AD patients.

To gain a better knowledge of the role of neurosteroids in dementia, we compared their concentrations in several brain regions between AD patients and aged nondemented controls. We also investigated the possible relationship between the neurosteroid levels and specific structural brain abnormalities related to AD, such as the extracellular senile plaques composed of  $\beta$ -amyloid peptides (A $\beta$ ) and the intracellular neurofibrillary tangles (NFT) constituted of intraneuronal bundles of paired helical filaments (PHF) that result from the aggregation of pathologic  $\tau$  proteins (PHF- $\tau$ ) (18, 19).

**Subjects and Methods**

*Subjects*

Eleven patients (median age, 86.3 yr; minimum, 75.6 yr; maximum, 91.5 yr) were selected for the study. They were hospitalized and died in a geriatric unit (Service de G erontologie 3, H opital Emile Roux, Limeil-Br evannes, France). Exclusion criteria were a postmortem delay beyond 24 h, steroid or benzodiazepine administration during the month before death, and prolonged hypoxemia at the time preceding death. Dementia was considered using the criteria of Mental Diagnosis and Statistical Manual Disorders, (20), and criteria of AD were those proposed by the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (21). All patients had a full clinical evaluation of neurological status and a specific complementary evaluation (cerebral tomography, electroencephalography, serological tests for syphilis and human immunodeficiency virus, and serum determinations of thyroid function, vitamin B<sub>12</sub>, folates, and calcium). At the time of autopsy, one hemisphere of each brain was formalin-fixed for neuropathological examination, and the other one was deep-frozen at -80 C until biochemical analysis. Patients were included on the basis of their clinical and biological diagnoses. The diagnosis of AD was excluded for six patients (nondemented control group: two women and four men) and was sustained for five others (AD group: four women and one man). All clinical investigations described here were approved by the local committee and conducted in accordance with the Declaration of Helsinki.

*Neuropathological examination of brain samples*

The neuropathological features of all patients were evaluated as in a previous study (22) and are detailed in Table 1. Briefly, the presence of amyloid plaques and NFT were scored in cortical and subcortical areas according to Consortium to Establish a Registry for Alzheimer's Disease criteria (23) and Braak and Braak's stages (24), respectively. Quantification of amyloid depositions was performed by counting the number of plaques per square millimeter, using thioflavine S and antibodies against Aβ peptides, *i.e.* monoclonal Aβ8-17 (DAKO Corp., Carpinteria, CA) or polyclonal antibodies against the N- and C-terminal part of Aβ 1-40 and Aβ 1-42 (INSERM, U-422, Lille, France). NFT were quantified by counting the numbers per square millimeter using monoclonal antibody AD2 directed against PHF-τ (25).

*Collection of brain regions*

Upon thawing of one cerebral hemisphere at -10 C, large portions of hippocampus, amygdala, frontal cortex, striatum, hypothalamus, and cerebellum were dissected out, and representative fractions of 100 mg of each brain structure were collected and immediately stored at -80 C. From a total of 66 samples (11 patients × 6 brain regions) to be collected,

**TABLE 1.** Neuropathological features of the aged nondemented and Alzheimer's patients

Group	Gender	Age (yr)	Histological classification	
			Amyloid plaques	NFT
Nondemented control	Woman	87.9	0	III
	Woman	90.3	A	III
	Man	75.6	0	II
	Man	80.9	0	I
	Man	86.3	A	II
	Man	91.5	A	I
Alzheimer's patients	Woman	81.4	C	V
	Woman	85.5	C	IV
	Woman	88.0	C	VI
	Woman	91.1	B	IV
	Man	86.0	C	V

Histological classification as evaluated previously (22). Amyloid plaques and NFT were classified in cortical areas according to the Consortium to Establish a Registry for Alzheimer's Disease criteria (23) and Braak and Braak's classification (24), with respect to the location and the density of amyloid plaques (0–C) and NFT (I–VI).

7 samples (1 hippocampus and 2 amygdala from controls as well as 2 amygdala and 1 hypothalamus from AD patients) were not included in the study because of difficulties in definite identification.

*Biochemical analysis of Aβ and PHF-τ proteins*

The levels of Aβ were quantified in homogenates of frontal cortex as in a previous study (22). Briefly, Aβ was identified by dot blot using the same immunological probes as those used for amyloid plaque detection, according to the procedure developed by Permanne *et al.* (26) and was quantified using the ImageMaster program developed by Amersham Pharmacia Biotech (Piscataway, NJ).

The levels of PHF-τ proteins were determined in all the brain regions collected. PHF-τ proteins were immunodetected by Western blot using monoclonal antibody AD2 as described for NFT detection, according to the method reported by Sergeant *et al.* (27). They were quantified, using the ImageMaster program, by measuring the area of the peaks corresponding to τ55, 64, and 69, which were then scored by comparison with a temporal cortex homogenate from a patient with early-onset AD, considered as a positive internal standard, as previously described (28).

*Biochemical analysis of steroids*

The method used for steroid analysis was previously described and validated (29). Briefly, after adding 3β,5β-tetrahydroandrostenedione (Sigma-Aldrich, St. Louis, MO) as the internal standard for PREG, DHEA, progesterone (PROG), 3α,5α-THP, and [<sup>3</sup>H<sub>4</sub>]PREGS ([17,21,21,21-<sup>3</sup>H]PREGS, trimethyl ammonium salt, prepared by Dr. R. Purdy, La Jolla, CA) as the internal standard for PREGS and DHEAS, the steroids were extracted by methanol 100%. The sulfated and unconjugated steroids were separated and purified by chromatography on AMPREP silica minicolumns C<sub>18</sub> (Amersham International, Little Chalfont, UK) using solutions of MeOH-H<sub>2</sub>O [40:60, (vol/vol) and 85:15 (vol/vol), respectively]. The sulfated steroid fraction was solvolysed with ethyl acetate containing 0.2% 0.5 M H<sub>2</sub>SO<sub>4</sub> (30) at room temperature for 1 h. The unconjugated steroid fraction was submitted to HPLC. The HPLC system from Thermoquest (San Jose, CA) consisted of a P1000XR quaternary pump and an AS 100 XR TSP autoinjector. HPLC was achieved with a Lichrosorb Diol column (25 cm × 4.6 mm, 5 μm). The solvent system consisted of hexane and mixture A (90:10, vol/vol), the latter composed of hexane-isopropanol (85:15, vol/vol). The elution was performed at a flow rate of 1 ml/min. The elution profiles of PREG, DHEA, PROG, and 3α,5α-THP were identical to those previously reported (29). The unconjugated steroids from the HPLC fractions and those obtained after solvolysis were then derivatized separately with anhydrous heptafluorobutyric acid (Pierce Chemical Co., Rockford, IL) before injection into the gas chromatography-mass spectrometry (GC-MS) system. GC was performed in the splitless mode with a GC 8000 Top gas chromatograph (Carlo Erba, Milan, Italy). The mass spectrometer (model 150, Finnigan Automass, Argenteuil, France) was operated in the electron impact mode. Identification was performed in the full-scan mode, and quantification was performed in the single ion monitoring mode. Each GC-MS measurement was made in duplicate.

*Statistical analysis*

Nonparametric tests were used. The Kruskal-Wallis test was used for overall comparisons between the two groups of patients followed and, when significant, by the Mann-Whitney test applied region by region. The Friedman test was used for overall comparisons between regions followed and, when significant, by the Wilcoxon test. Statistical associations between two sets of independent and continuous data were assessed by the Spearman test. Data are presented as the mean ± SEM. Significance was defined at P < 0.05.

**Results**

*Age and sex characteristics*

Six patients were assigned to the control group, and five patients constituted the AD group. In the control and AD groups, the median ages were 87.1 and 86.0 yr, respectively, and there was no significant difference in age (P > 0.999) or

AQ: B

in sex ratio (by Fisher's exact test,  $P = 0.242$ ) between the two groups. Women were slightly older than men (median, 87.9 and 86.0 yr, respectively), but no significant difference was found with age according to sex ( $P = 0.361$ ).

*Steroid quantification in brain regions*

As indicated in Figs. 1–3 the steroids found at the highest concentrations were in decreasing order (PREG > DHEA > PROG, > PREGS > DHEAS >> 3 $\alpha$ ,5 $\alpha$ -THP) in all regions of both groups. No difference was noted between regions in the AD group. In contrast, a significant overall difference between regions was observed in the control group for each steroid measured (PREGS,  $P < 0.05$ ; other steroids,  $P < 0.01$ ), except for 3 $\alpha$ ,5 $\alpha$ -THP ( $P = 0.097$ ). In this group, regions containing the highest levels of steroids were, in decreasing order, hypothalamus > striatum > frontal cortex > cerebellum > amygdala  $\approx$  hippocampus. Region by region comparisons in the control group revealed that the levels of all steroids measured, except 3 $\alpha$ ,5 $\alpha$ -THP, were always significantly lower in the hippocampus and frontal cortex than in the hypothalamus ( $P < 0.05$ ) and also in the striatum for the sulfated steroids ( $P < 0.05$ ). Moreover, free steroids (*i.e.* PREG, DHEA, and PROG) exhibited a significantly lower level in the cerebellum than in the hypothalamus ( $P < 0.05$ ).

A general trend toward lower levels of steroids was observed in the six brain regions of the AD patients compared with the controls. An overall significant regional difference




FIG. 1. Concentrations of PREGS and DHEAS in six brain regions of nondemented (□) and AD (■) patients. HC, Hippocampus; A, amygdala; FC, frontal cortex; ST, striatum; HT, hypothalamus; C, cerebellum. Values are the mean  $\pm$  SEM. \*,  $P < 0.05$  (by Mann-Whitney test).




FIG. 2. Concentrations of PREG and DHEA in six brain regions of nondemented (□) and AD (■) patients. HC, Hippocampus; A, amygdala; FC, frontal cortex; ST, striatum; HT, hypothalamus; C, cerebellum. Values are the mean  $\pm$  SEM.

was found between the two groups for PREGS ( $P < 0.001$ ) and DHEAS ( $P < 0.001$ ; Fig. 1). PREGS was significantly lower in the striatum ( $P < 0.05$ ) and cerebellum ( $P < 0.05$ ) of AD patients than in controls and was close to a significant level of difference in the frontal cortex ( $P = 0.068$ ). DHEAS was significantly lower in the AD group compared with controls in the striatum ( $P = 0.029$ ), cerebellum ( $P = 0.011$ ), and hypothalamus ( $P = 0.019$ ).

*Relationship among the levels of brain steroids, PHF- $\tau$  proteins, and A $\beta$*

The levels of PHF- $\tau$  proteins were significantly higher in the AD group compared with the controls in all brain regions ( $P < 0.05$ ) except the amygdala, for which the difference was just above the level of significance ( $P = 0.077$ ) despite the four samples missing, and the cerebellum, in which PHF- $\tau$  proteins were undetectable in all patients (Fig. 4). A significant negative correlation was observed between the PHF- $\tau$  proteins and DHEAS levels in the hypothalamus ( $P < 0.05$ ;  $\rho = -0.717$ ), and no relationship was found for the other steroids analyzed.

The levels of A $\beta$  in the frontal cortex were significantly higher in the AD patients compared with the control group (respectively,  $67.8 \pm 20.8$  and  $2.2 \pm 2.0$  nmol/kg brain tissue, respectively;  $P = 0.008$ ). A significant negative correlation was found between the levels of cortical A $\beta$  and PREGS in the striatum ( $P < 0.05$ ;  $\rho = -0.718$ ) and cerebellum ( $P < 0.05$ ;

F4




FIG. 3. Concentrations of PROG and 3α,5α-THP in six brain regions of nondemented (□) and AD (■) patients. HC, Hippocampus; A, amygdala; FC, frontal cortex; ST, striatum; HT, hypothalamus; C, cerebellum. Values are the mean ± SEM.




FIG. 4. Concentrations of PHF-τ in six brain regions of nondemented (□) and AD (■) patients, expressed as a percentage of the positive control value (22). HC, Hippocampus; A, amygdala; FC, frontal cortex; ST, striatum; HT, hypothalamus; C, cerebellum; n.d., not detected. Values are the mean ± SEM. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$  (by Mann-Whitney test).

$\rho = -0.729$ ). DHEAS concentrations were also negatively correlated with Aβ levels in these two structures, but were at the threshold of significance ( $P = 0.094$  and  $P = 0.055$ , respectively). In the other brain regions studied, there were no significant correlations between the levels of Aβ and those of DHEAS, PREGS, or any other steroid.

### Discussion

The present study is the first report, to the best of our knowledge, of a comparative analysis of the concentrations of several neurosteroids, determined by GC-MS, in various brain regions between aged AD patients and aged nondemented controls. Compared with RIA, the technique employed here, coupling HPLC and GC-MS, offers the advantage of high sensitivity and specificity and allows the simultaneous quantification of different steroids in individual tissue samples (29). This methodology allowed us to compare the levels of various neurosteroids in specific brain regions between AD patients and nondemented controls. Despite the rise in interindividual variability that occurs during aging, differences in brain steroid levels between the AD group and controls were observed.

In the human brain, numerous steroids have already been quantified, such as PREG and DHEA (12, 31), PREGS and DHEAS (31), PROG (10, 11, 31), and 3α,5α-THP (10). To date, no study has used GC-MS technology to quantify steroids in the human brain, thus making difficult the comparison of our GC-MS values with the previously published RIA measurements. In addition, only a few studies have analyzed more than three human brain regions, and the regions that were chosen were generally different from one study to another (9, 10, 12, 31).

According to previous measurements of neurosteroids in the human brain using RIA, only the study by Lanthier *et al.* (31) has provided data on the levels of PREGS and DHEAS in brain regions of five patients. These researchers also assayed PREG and DHEA, as did Lacroix *et al.* (12), specifically in the cortex and cerebellum of 10 subjects. Comparisons between our data and those of the cited studies revealed that the differences in the concentrations of neurosteroids (PREG, DHEA, PREGS, and DHEAS) in control patients are limited to the hypothalamus, where our values were 2- to 4-fold higher than those found by the others. Apart from this difference, our steroid measurements in the frontal cortex, amygdala, and hippocampus are in the same range and to the best of our knowledge, we are the first to describe the concentrations of PREG, DHEA, PREGS, and DHEAS in the striatum. In the previous reports old subjects were used, but their neurological status was not described despite the high prevalence of neurological diseases in this age class. Significant differences between the two groups of patients were found in several regions for DHEAS and PREGS. It is of importance to highlight that these two steroids are those that have shown the greatest evidence for a neuroprotective effect (8, 32–35). Cerebral concentrations of DHEA and PREG in the present study were much higher (in the range of 5.69–201.99 nmol/kg for DHEA and 11.09–1011.33 nmol/kg for PREG, depending on the brain regions) than those reported in the blood of very old patients (13, 36, 37), consistent with the postulate of local production of DHEA and PREG in the human brain.

Measurements of PROG in specific regions of the brain of elderly subjects have been reported, but a great heterogeneity could be observed among the values. Overall values from the control patients of our study are either clearly higher than some of those previously reported (10–12, 31) or very similar

to those of the oldest subgroup (women; median age, 75 yr) of subjects in the study by Bixo *et al.* (10). To date, quantification of  $3\alpha,5\alpha$ -THP in the human brain has only been reported in one study (10). In that work, conducted upon much younger subjects than those in our study, the  $3\alpha,5\alpha$ -THP values were 20 times higher in the cortex and hypothalamus and 30 times higher in the striatum and cerebellum compared with those in the corresponding brain areas in the controls of the present study.

AD is the most common cause of dementia in the elderly. One line of research to explain the pathogenesis of this neurological disorder is currently oriented toward examination of the possible relationships between specific structural, metabolic, and neurochemical brain abnormalities (for review, see Ref. 38). Natural progression of AD involves first the hippocampus and neocortex, but also other areas of the limbic system, such as the amygdala and olfactory bulbs (39), and extends progressively to cortical brain areas during the course of AD (22). The involvement of basal nuclei, such as hypothalamus or striatum, and the cerebellum occurs later in the progression of the disease (40, 41).

We demonstrate here for the first time that two biochemical hallmarks of AD, namely PHF- $\tau$  and A $\beta$ , are correlated with the levels of the neurosteroids PREGS and DHEAS in distinct brain regions. Our results revealed that PHF- $\tau$  levels were significantly and negatively correlated with the DHEAS concentration in the hypothalamus. They also indicated that the levels of cortical A $\beta$  were significantly and negatively correlated with PREGS levels and to some extent with DHEAS in the striatum and cerebellum. It is known that a widespread neuronal loss occurs during the course of AD that could be in part causal or consecutive to the lower steroid levels observed in AD brains. The absence of a relationship between the levels of PHF- $\tau$  and steroids, particularly in the hippocampus and cerebral cortex, is consistent with the fact that NFT, which are the histological hallmark of high levels of PHF- $\tau$ , are known to always be present in the hippocampus and entorhinal cortex of very old patients regardless of their state of dementia (22, 42, 43). These findings are supportive of the role of DHEAS in the protection against A $\beta$ -induced neurotoxicity (7, 8) and in the enhancement of APP production (44).

In conclusion, this study provides reference values, determined by GC-MS, for steroid concentrations in various regions of the aged human brain. High levels of key proteins implicated in the formation of plaques and NFT were correlated with decreased brain levels of PREGS and DHEAS, thus suggesting a possible protective role for these neurosteroids in the dementia related to AD.

### Acknowledgments

Received June 5, 2002. Accepted August 14, 2002.


Address all correspondence and requests for reprints to: Sebastien Weill-Engerer, M.D., INSERM, U-488, Stéroïdes et Système Nerveux, 80 rue du Général Leclerc, 94276 Le Kremlin-Bicêtre, France. E-mail: sebastien@kb.inserm.fr.

This work was supported in part by a grant from the European Communities (QLK 6-CT-2000-00179), the Fondation Nationale de Gérologie (Paris, France), and the Leila Y. Mathers and Florence Gould Foundations (New York, NY).

### References

- Baulieu EE 1991 Neurosteroids: a new function in the brain. *Biol Cell* 71:3–10
- Lambert JJ, Belleli D, Shepherd SE, Pistis M, Peters JA 1999 The selective interaction of neurosteroids with the GABA<sub>A</sub> receptor. In: Baulieu EE, Robel P, Schumacher M, eds. Neurosteroids: a new regulatory function in the nervous system. Totowa: Humana Press; 125–142
- Akwa Y, Baulieu EE 1999 Neurosteroids: behavioral aspects and physiological implications. *J Soc Biol* 193:293–298
- Mathis C, Paul SM, Crawley JN 1994 The neurosteroid pregnenolone sulfate blocks NMDA antagonist-induced deficits in a passive avoidance memory task. *Psychopharmacology* 116:201–206
- Flood JF, Roberts E 1988 Dehydroepiandrosterone sulfate improves memory in aging mice. *Brain Res* 448:178–181
- Gursoy E, Cardounel A, Kalimi M 2001 Pregnenolone protects mouse hippocampal (HT-22) cells against glutamate and amyloid  $\beta$  protein toxicity. *Neurochem Res* 26:15–21
- Cardounel A, Regelson W, Kalimi M 1999 Dehydroepiandrosterone protects hippocampal neurons against neurotoxin-induced cell death: mechanism of action. *Proc Soc Exp Biol Med* 222:145–149
- Mao X, Barger SW 1998 Neuroprotection by dehydroepiandrosterone-sulfate: role of an NF $\kappa$ B-like factor. *NeuroReport* 9:759–763
- Bixo M, Backstrom T, Winblad B, Andersson A 1995 Estradiol and testosterone in specific regions of the human female brain in different endocrine states. *J Steroid Biochem Mol Biol* 55:297–303
- Bixo M, Andersson A, Winblad B, Purdy RH, Backstrom T 1997 Progesterone,  $5\alpha$ -pregnane-3,20-dione and  $3\alpha$ -hydroxy- $5\alpha$ -pregnane-20-one in specific regions of the human female brain in different endocrine states. *Brain Res* 764:173–178
- Hammond GL, Hirvonen J, Vihko R 1983 Progesterone, androstenedione, testosterone,  $5\alpha$ -dihydrotestosterone and androsterone concentrations in specific regions of the human brain. *J Steroid Biochem* 18:185–189
- Lacroix C, Fiet J, Benais JP, Gueux B, Bonete R, Villette JM, Gourmel B, Dreux C 1987 Simultaneous radioimmunoassay of progesterone, androst-4-enedione, pregnenolone, dehydroepiandrosterone and 17-hydroxyprogesterone in specific regions of human brain. *J Steroid Biochem* 28:317–325
- Morley JE, Kaiser F, Raum WJ, Perry HM, 3rd, Flood JF, Jensen J, Silver AJ, Roberts E 1997 Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. *Proc Natl Acad Sci USA* 94:7537–7542
- Ferrario E, Massaia M, Aimo G, Pallavicino di Ceva A, Fabris F 1999 Dehydroepiandrosterone sulfate serum levels: no significance in diagnosing Alzheimer's disease. *J Endocrinol Invest* 22:81
- Hillen T, Lun A, Reischies FM, Borchelt M, Steinhagen-Thiessen E, Schaub RT 2000 DHEA-S plasma levels and incidence of Alzheimer's disease. *Biol Psychiatry* 47:161–163
- Leblhuber F, Neubauer C, Peichl M, Reisecker F, Steinparz FX, Windhager E, Dienstl E 1993 Age and sex differences of dehydroepiandrosterone sulfate (DHEAS) and cortisol (CRT) plasma levels in normal controls and Alzheimer's disease (AD). *Psychopharmacology* 111:23–26
- Yanase T, Fukahori M, Taniguchi S, Nishi Y, Sakai Y, Takayanagi R, Haji M, Nawata H 1996 Serum dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEA-S) in Alzheimer's disease and in cerebrovascular dementia. *Endocr J* 43:119–123
- Braak H, Braak E 1991 Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. *Brain Pathol* 1:213–216
- Glenner GG 1988 Alzheimer's disease: its proteins and genes. *Cell* 52:307–308
- American Psychiatric Association 1987 DSM-III-R. Diagnostic and statistical manual of mental disorders. Washington DC: APA Press
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM 1984 Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* 34:939–944
- Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P, Ghzali F, Fallet-Bianco C, Pasquier F, Lebert F, Petit H, Di Menza C 1999 The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. *Neurology* 52:1158–1165
- Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L 1991 The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* 41:479–486
- Braak H, Braak E 1991 Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol* 82:239–259
- Buee-Scherrer V, Condamin O, Mourton-Gilles C, Jakes R, Goedert M, Pau B, Delacourte A 1996 AD2, a phosphorylation-dependent monoclonal antibody directed against  $\tau$  proteins found in Alzheimer's disease. *Brain Res Mol Brain Res* 39:79–88
- Permanne B, Buee L, David JP, Fallet-Bianco C, Di Menza C, Delacourte A 1995 Quantitation of Alzheimer's amyloid peptide and identification of related amyloid proteins by dot-blot immunoassay. *Brain Res* 685:154–162
- Sergeant N, David JP, Goedert M, Jakes R, Vermersch P, Buee L, Lefranc D,

- Wattez A, Delacourte A 1997 Two-dimensional characterization of paired helical filament- $\tau$  from Alzheimer's disease: demonstration of an additional 74-kDa component and age-related biochemical modifications. *J Neurochem* 69:834–844
28. Vermersch P, Frigard B, Delacourte A 1992 Mapping of neurofibrillary degeneration in Alzheimer's disease: evaluation of heterogeneity using the quantification of abnormal  $\tau$  proteins. *Acta Neuropathol* 85:48–54
29. Liere P, Akwa Y, Weill-Engerer S, Eychenne B, Pianos A, Robel P, Sjoval J, Schumacher M, Baulieu EE 2000 Validation of an analytical procedure to measure trace amounts of neurosteroids in brain tissue by gas chromatography-mass spectrometry. *J Chromatogr B Biomed Sci Appl* 739:301–312
30. Shimada K, Mukai Y, Yago K 1998 Studies on neurosteroids. VII. Characterization of pregnenolone, its sulfate and dehydroepiandrosterone in rat brains using liquid chromatography/mass spectrometry. *J Liq Chrom Rel Technol* 21:765–775
31. Lanthier A, Patwardhan VV 1986 Sex steroids and 5-en- $3\beta$ -hydroxysteroids in specific regions of the human brain and cranial nerves. *J Steroid Biochem* 25:445–449
32. Maurice T, Su TP, Privat A 1998  $\sigma 1$  (sigma 1) receptor agonists and neurosteroids attenuate  $\beta 25$ –35-amyloid peptide-induced amnesia in mice through a common mechanism. *Neuroscience* 83:413–428
33. Roberts E, Bologna L, Flood JF, Smith GE 1987 Effects of dehydroepiandrosterone and its sulfate on brain tissue in culture and on memory in mice. *Brain Res* 406:357–362
34. Bologna L, Sharma J, Roberts E 1987 Dehydroepiandrosterone and its sulfated derivative reduce neuronal death and enhance astrocytic differentiation in brain cell cultures. *J Neurosci Res* 17:225–234
35. Kimonides VG, Khatibi NH, Svendsen CN, Sofroniew MV, Herbert J 1998 Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. *Proc Natl Acad Sci USA* 95:1852–1857
36. Hill M, Lukac D, Lapcik O, Sulcova J, Hampl R, Pouzar V, Starka L 1999 Age relationships and sex differences in serum levels of pregnenolone and 17-hydroxypregnenolone in healthy subjects. *Clin Chem Lab Med* 37:439–447
37. Labrie F, Belanger A, Cusan L, Gomez JL, Candas B 1997 Marked decline in serum concentrations of adrenal  $C_{19}$  sex steroid precursors and conjugated androgen metabolites during aging. *J Clin Endocrinol Metab* 82:2396–2402
38. Cummings JL, Vinters HV, Cole GM, Khachaturian ZS 1998 Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. *Neurology* 51:S2–S17
39. Goldman J, Côté L, Schwartz JH, Jessel TM 1991 Aging of the brain: dementia of the Alzheimer's type. In: Kandel EK, ed. *Principles of neural science*, 3rd Ed. Amsterdam: Elsevier; 974–983
40. Joachim CL, Morris JH, Selkoe DJ 1989 Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. *Am J Pathol* 135:309–319
41. Wolf DS, Gearing M, Snowdon DA, Mori H, Markesbery WR, Mirra SS 1999 Progression of regional neuropathology in Alzheimer disease and normal elderly: findings from the Nun study. *Alzheimer Dis Assoc Disord* 13:226–231
42. Giannakopoulos P, Hof PR, Giannakopoulos AS, Herrmann FR, Michel JP, Bouras C 1995 Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of very old patients. *Arch Neurol* 52:1150–1159
43. Price JL, Morris JC 1999 Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. *Ann Neurol* 45:358–368
44. Danenberg HD, Haring R, Heldman E, Gurwitz D, Ben-Nathan D, Pittel Z, Zuckerman A, Fisher A 1995 Dehydroepiandrosterone augments M1-muscarinic receptor-stimulated amyloid precursor protein secretion in desensitized PC12MI cells. *Ann NY Acad Sci* 774:300–303



## AUTHOR QUERIES

### AUTHOR PLEASE ANSWER ALL QUERIES

1

A—Au; please give postal code for each city in affiliation line

B—au; significance test sentence punctuation correct for meaning? See following sentence also

C—au; please write out APP

---

---